

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application: Claims 1-16 and 21-28 have been canceled.

Listing of Claims:

Claims 1-16 (CANCELED)

17. (Previously Presented) A tumor cell composition comprising a tumor cell modified to express a B7-2 protein and at least one additional immune modulator, or a functional fragment of said B7-2 protein or said immune modulator.

18. (Previously Presented) The tumor cell composition according to claim 17, wherein said at least one additional immune modulator is a cytokine protein.

19. (Previously Presented) The tumor cell composition according to claim 18, wherein said cytokine protein is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-gamma, and tumor necrosis factor-alpha.

20. (Previously Presented) The tumor cell composition according to claim 18, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.

Claims 21-28 (CANCELED)

29. (Previously Presented) A method for the treatment or prevention of cancer comprising: a) providing a polynucleotide encoding a B7-2 protein and at least one additional immune modulator, or a functional fragment of said B7-2 protein or said immune modulator; b) transferring said polynucleotide into cancer cells under conditions such that said B7-2 protein and said immune modulator are expressed by at least a portion of said cancer cells; and c) administering an effective amount of the modified cancer cells of step b) to a patient.

30. (Previously Presented) The method according to claim 29 further comprising irradiating said cancer cells expressing said B7-2 protein and said immune modulator prior to administering said irradiated cancer cells into said patient.

31. (Previously Presented) The method according to claim 30, further comprising introducing at least one additional dose of irradiated cancer cells expressing said B7-2 protein and said immune modulator into said immunized subject.

32. (Previously Presented) The method according to claim 29, wherein said at least one additional immune modulator is a cytokine protein.

33. (Previously Presented) The method according to claim 32, wherein said cytokine protein is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-gamma, and tumor necrosis factor-alpha.

34. (Previously Presented) The method according to claim 32, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.

35. (Previously Presented) The method according to claim 29, wherein said polynucleotide is transferred by a viral vector.

36. (Previously Presented) The method according to claim 35, wherein said viral vector is a retroviral vector.

37. (Previously Presented) The method according to claim 35, wherein said viral vector is an adenoviral vector.

38. (Previously Presented) The method according to claim 29, wherein said polynucleotide is encapsulated by, or complexed with, a liposome.

39. (Previously Presented) The method according to claim 29, wherein said cancer cells are from a solid tumor.

40. (Previously Presented) The method according to claim 29, wherein said cancer cells are from a brain tumor.

41. (Previously Presented) The method according to claim 40, wherein said brain tumor is a glioblastoma.

42. (Previously Presented) The method according to claim 29, wherein said cancer cells are from a melanoma.

43. (Previously Presented) A method for the treatment or prevention of cancer comprising administering to a subject in need thereof an effective amount of a tumor vaccine comprising a tumor cell modified to express a B7-2 protein and at least one additional immune modulator, or a functional fragment of said B7-2 protein or said immune modulator.

44. (Previously Presented) The method according to claim 43, wherein said at least one additional immune modulator is a cytokine protein.

45. (Previously Presented) The method according to claim 44, wherein said cytokine protein is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-gamma, and tumor necrosis factor-alpha.

46. (Previously Presented) The method according to claim 43, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.

47. (Previously Presented) The method according to claim 43, wherein said cancer cells are from a tumor.

48. (Previously Presented) The method according to claim 43, wherein said cancer cells are from a brain tumor.

49. (Previously Presented) The method according to claim 48, wherein said brain tumor is a glioblastoma.

50. (Previously Presented) The method according to claim 43, wherein said cancer cells are from a melanoma.